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A B S T R A C T
Background: Several neurodegeneration (N) metrics using structural MRI are used for the purpose of Alzheimer's
disease (AD)-related staging, including hippocampal volume, global atrophy, and an “AD signature” composite
consisting of thickness or volumetric estimates derived from regions impacted early in AD. This study sought to
determine if less user-intensive estimates of global atrophy and hippocampal volume were equivalent to a
thickness-based AD signature from FreeSurfer for defining N across the AD continuum (i.e., individuals who are
amyloid-positive (A+)).
Methods: Cognitively unimpaired (CU) late middle-aged and older adults, as well as A+ mild cognitive im-
pairment (MCI) and A+ AD dementia individuals, with available CSF and structural MRI scan< 1.5 years apart,
were selected for the study (n=325, mean age=62). First, in a subsample of A+ AD dementia and matched
biomarker-negative (i.e., A- and tau tangle pathology (T)-) CU controls (n=40), we examined ROC char-
acteristics and identified N cut-offs using Youden's J for neurofilament light chain protein (NfL) and each of three
MRI-based measures: a thickness-based AD signature from FreeSurfer, hippocampal volume (using FIRST), and a
simple estimate of global atrophy (the ratio of intracranial CSF segmented volume to brain tissue volume, using
SPM12). Based on the results from the ROC analyses, we then examined the concordance between NfL N po-
sitivity and N positivity for each MRI-based metric using Cohen's Kappa in the remaining subsample of 285
individuals. Finally, in the full sample (n=325), we examined the relationship between the four measures of N
and group membership across the AD continuum using Kruskal-Wallis tests and Cliff's deltas.
Results: The three MRI-based metrics and CSF NfL similarly discriminated between the A-T- CU (n=20) and A+
AD (n=20) groups (AUCs ≥0.885; ps < 0.001). Using the cut-off values derived from the ROCs to define N
positivity, there was weak concordance between NfL and all three MRI-derived metrics of N in the subsample of
285 individuals (Cohen's Kappas ≤0.429). Finally, the three MRI-based measures of N and CSF NfL showed
similar associations with AD continuum group (i.e., Kruskal-Wallis ps < 0.001), with relatively larger effect
sizes noted when comparing the A-T- CU to the A+ MCI (Cliff's deltas ≥0.741) and A+ AD groups (Cliff's deltas
≥0.810) than to the A+T- CU (Cliff's deltas= 0.112–0.298) and A+T+ CU groups (Cliff's
deltas= 0.212–0.731).
Conclusions: These findings suggest that the three MRI-based morphometric estimates and CSF NfL similarly
differentiate individuals across the AD continuum on N status. In many applications, a simple estimate of global
atrophy may be preferred as an MRI marker of N across the AD continuum given its methodological robustness
and ease of calculation when compared to hippocampal volume or a cortical thickness AD signature.
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1. Introduction
The preclinical phase of Alzheimer's disease (AD), which is thought
to begin a decade or more prior to a clinical diagnosis of dementia due
to AD, is characterized by neuropathological changes but intact cog-
nitive and functional abilities (Price et al., 2009; Price and Morris,
1999). Several biomarkers exist for detecting AD-related neuro-
pathology in vivo across the AD continuum. Recently, Jack and col-
leagues proposed a framework for defining abnormal pathophysiology
in AD by dividing these biomarkers into three distinct categories (Jack
et al., 2016, 2018) of amyloid burden (A) (e.g., decreased cerebrospinal
fluid (CSF) levels of Aβ42 or elevated retention of amyloid PET tracers),
tau tangle pathology (T) (e.g., elevations in tau tracer retention on PET
or increased CSF levels of phosphorylated tau (ptau181)), and neuro-
degeneration (N) (e.g., [18F]-fluorodeoxyglucose (FDG)-PET hypome-
tabolism, elevated CSF levels of total tau, or gray matter loss measured
using structural MRI). Within the context of this AT(N) framework,
individuals can be categorized as A, T, and/or N positive or negative,
resulting in eight possible groups.
In order to classify individuals across the AD continuum (i.e., in-
dividuals who are A+) using A, T, and N, one must first develop cut-off
values for each of these three categories of biomarkers, and such
thresholds may be site-specific. Numerous studies demonstrate sensitive
and specific cut-off values for both A and T in individuals in the earliest
stages of AD (e.g., Clark et al., 2018; Hansson et al., 2006; Mattsson
et al., 2014; Sjögren et al., 2001), and the field is improving precision in
this regard with new CSF platforms for analysis (Bittner et al., 2016;
Vandijck et al., 2017). There is relatively greater heterogeneity in de-
fining N across the AD continuum, particularly with MRI. MRI mor-
phometric approaches for assessing atrophy are abundant, but may vary
at several levels including acquisition (field strength and sequence
parameters), neuroanatomic operationalization of structures of interest,
choice of software, reliability and precision of the measure of interest,
computational availability, and end-user expertise and decision rules to
evaluate the output. Furthermore, unlike A and T, N is not necessarily
specific to AD pathophysiology. For example, a marked increase in CSF
total tau (as a surrogate indicator of N) is seen both with acute brain
damage, such as ischemic stroke (Hesse et al., 2001), as well as in ra-
pidly progressive neurodegenerative disorders such as Creutzfeldt-
Jakob disease (Skillbäck et al., 2014). Nevertheless, prior investigations
report that A+T+N+ individuals are more likely to evidence cog-
nitive decline than not only A-T-N- individuals, but also their
A+T+N- counterparts (Aschenbrenner et al., 2018; Bouwman et al.,
2007; Davatzikos et al., 2011; Jack et al., 2017; Soldan et al., 2019; van
Maurik et al., 2017; van Rossum et al., 2012; Vemuri et al., 2009).
These findings suggest that N, in conjunction with A and T, may provide
important staging information for AD (Jack et al., 2018).
A number of N metrics are currently available for AD-related sta-
ging. One of the most readily available methods comes from morpho-
metric estimates obtained using structural MRI. Structural MRI studies
examining N in AD have frequently focused on hippocampal volume
(Jack et al., 1992; Storandt et al., 2009; van Maurik et al., 2017), global
atrophy (Fagan et al., 2009; Fox et al., 1999; Schott et al., 2010; van
Maurik et al., 2017), and an “AD signature” consisting of a composite of
thickness or volumetric estimates derived from regions impacted early
during the course of AD (Dickerson et al., 2011; Dickerson and Wolk,
2012; Schwarz et al., 2016). A previous study, which compared mul-
tiple thickness- and volumetric-based methods for obtaining an AD
signature, found that thickness-based AD signatures from FreeSurfer
and Statistical Parametric Mapping (SPM)+DiReCT (the cortical
thickness algorithm from Advanced Normalization Tools (ANTs)) had
the strongest correlations with Braak neurofibrillary tangle stage at
autopsy (Schwarz et al., 2016). It should be noted that SPM+DiReCT
was found to have better test-retest reliability than FreeSurfer, although
FreeSurfer performed better in terms of diagnostic separability. As a
result, Schwarz et al. recommended either method as appropriate for
obtaining an AD signature estimate.
Compared to completely automated methods, FreeSurfer can re-
quire iterative manual editing of segmentation output and this practice
may vary between laboratories. Further, the automated segmentation
component itself can be time consuming, with a recent study suggesting
that FreeSurfer 6.0 takes approximately 6–9 h per scan to complete this
component (Ellis et al., 2016), with the total amount of time depending
upon a number of parameters (e.g., processor speed and workflow type)
and control point editing iterations. Given these drawbacks, it may be
that less user- and computationally-intensive estimates obtained from
structural MRI with quicker quality control procedures, such as hip-
pocampal volume and global atrophy estimates derived from FMRIB
Software Library (FSL)-FIRST (a tool designed to segment subcortical
structures) and SPM respectively, are sufficient in many settings for
defining N in the context of AD.
One way to determine whether hippocampal volume and global
atrophy are equivalent to the thickness-based AD signature from
FreeSurfer is to follow a similar approach as outlined in Schwarz et al.
(2016) by comparing the diagnostic accuracy of these three estimates
for separating individuals with AD dementia from cognitively unim-
paired (CU) individuals. Alternatively, we could compare the three
MRI-based morphometric estimates to a reference standard. Un-
fortunately, no “gold standard” for defining N currently exists; how-
ever, CSF levels of neurofilament light chain protein (NfL) may be a
relatively good reference standard in light of prior investigations.
Several previous studies have demonstrated that CSF NfL is a bio-
marker of axonal injury in multiple neurodegenerative conditions, in-
cluding AD (Olsson et al., 2016; Petzold, 2005; Zetterberg, 2016;
Zetterberg et al., 2016). Furthermore, CSF NfL has been found to be
associated with accelerated disease progression and atrophy rates (both
hippocampal and whole brain), as well as differentiates individuals
with AD from CU individuals and those with mild cognitive impairment
(MCI) (Zetterberg et al., 2016). A prior meta-analysis noted that CSF
NfL had a large effect size for differentiating CU individuals from those
with AD, whereas CSF levels of other N markers (e.g., visinin-like
protein 1 and neuron-specific enolase) only demonstrated moderate
effect sizes (Olsson et al., 2016). Finally, recent research has found
elevated CSF levels of NfL in both symptomatic and asymptomatic
carriers of the presenilin-1 or amyloid precursor protein mutation, as
well as noted associations between CSF NfL and both cognitive and
imaging measures (e.g., global atrophy rate) in this group with familial
AD (Weston et al., 2017). Together, these findings suggest that CSF NfL
is a useful metric for defining N across the AD continuum, including
during the earliest phase of the disease.
In light of the findings reviewed above, the primary goal of the
current study was to compare the more computationally expensive and
user intensive AD signature to automated, robust, and computationally
efficient estimates of hippocampal volume and global atrophy for the
purpose of defining N in individuals across the AD continuum (i.e.,
individuals who are A+). To accomplish this goal, we: 1) examined the
diagnostic accuracy of each measure for separating A+ AD individuals
from A-T- CU individuals; 2) identified cut-off values for several mea-
sures of N; 3) evaluated the association between N defined using CSF
NfL and the three MRI-based measures; and 4) examined the ability of
these N measures to differentiate A-T- CU individuals from those along
the AD continuum (i.e., from A+T- CU to A+ AD individuals).
2. Materials and methods
2.1. Participants
Participants consisted of late middle-aged and older adults
(n=325, mean age= 62; 309 individuals reported their race as White,
1 as Hispanic, 6 as Black or African American, 2 as Asian, and 7 as
Native American or Alaskan Native; see Table 1 for sample character-
istics) enrolled in longitudinal cohort studies at the Wisconsin
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Alzheimer's Disease Research Center (WADRC) or the Wisconsin Reg-
istry for Alzheimer's Disease Prevention (WRAP; Johnson et al., 2018).
To qualify for the current analysis, participants were required to have at
least one T1-weighted structural MRI scan (to define N) and one lumbar
puncture (with available CSF data for Aβ42, ptau181, total tau, and NfL)
within 1.5 years of each other (mean time between lumbar puncture
and MRI scan=0.03 years, standard deviation=0.14 years,
range= 0–1.17 years). Participants were also required to be classified
as CU (i.e., no clinical diagnosis of MCI or dementia), MCI due to AD, or
dementia due to AD. These classifications were made by a team of
clinicians (neuropsychologists, physician dementia specialists, and
nurse practitioners) blind to biomarker status, and were based on
consensus conference research criteria established by the National In-
stitute on Aging-Alzheimer's Association (Albert et al., 2011; McKhann
et al., 2011). Participants were then categorized as biomarker negative
(i.e., A-T-) or biomarker positive (A+) based on available CSF data (for
more details about cut-off values for A and T, see the section on amyloid
and tau status determination below). Participants in the MCI or de-
mentia due to AD groups were required to be A+ and participants in
the CU group were required to be either A-T-, A+T-, or A+T+ so as to
represent individuals across the AD continuum (Jack et al., 2018). All
participants were free from major psychiatric conditions (e.g., schizo-
phrenia or bipolar disorder) and excluded from the current analysis if
they failed processing or had an abnormal MRI as described below (see
Supplemental Fig. 1 for a flow diagram detailing eligibility for the
current study).
The inclusion of human participants was approved by the University
of Wisconsin-Madison Institutional Review Board, and all participants
provided informed consent. The current work was carried out in ac-
cordance with The Code of Ethics of the World Medical Association.
2.1.1. ROC participants
A+ individuals with a clinical diagnosis of probable AD dementia
were matched to biomarker-negative CU individuals (i.e., A-T- in-
dividuals based on available CSF) on the following demographic vari-
ables: age, sex, and education. Six individuals with dementia due to AD
were excluded from the analysis because there was not an age-, sex-,
and education-matched biomarker-negative CU individual available.
This resulted in 20 A+ individuals with a clinical diagnosis of probable
AD and 20 A-T- CU individuals for the ROC analyses. Of the 20 A+
individuals with a clinical diagnosis of probable AD, 18 were A+T+
and 2 were A+T-. The Clinical Dementia Rating Scale (CDR; Morris,
1993) was administered to informants of these 20 participants to de-
termine the severity of dementia (9 were classified as CDR=0.5 (i.e.,
very mild dementia) and 11 were classified as CDR=1.0 (i.e., mild
dementia)). For more information on the demographic characteristics
of these individuals, please refer to Table 1 (ROC sample).
2.1.2. Participants used for NfL N concordance analysis
A-T- CU individuals who were not included in the ROC analyses,
along with CU and MCI individuals who were A+, were included in
analyses examining the relationship between N positivity by NfL and
the MRI-based measures of N. This resulted in the inclusion of 285
individuals with known biomarker status in these analyses. For in-
formation on the demographic characteristics of these individuals,
please refer to Table 1 (Concordance Sample).
2.2. Structural MRI
Two identical GE 3.0 Tesla MR750 scanners (Waukesha, WI, USA)
with an 8-channel head coil (Excite HD Brain Coil; GE Healthcare) were
used to acquire a T1-weighted brain volume in the axial plane, with a 3-
D inversion-recovery prepared fast spoiled gradient-echo sequence
using the following parameters: inversion time (TI)= 450ms, repeti-
tion time (TR)=8.1ms, echo time (TE)= 3.2ms, flip angle= 12°,
acquisition matrix= 256×256×156mm, field of view
(FOV)=256mm, slice thickness= 1.0mm. Additionally, seven sub-
jects were scanned with a shorter sequence that was less susceptible to
motion artifacts, after it was determined their first scan would likely be
unusable. The shorter sequence parameters were: TI= 450ms,
TR=6.044ms, TE=2.204ms, flip angle= 12°, acquisition ma-
trix= 256×256×130mm, FOV=256mm, slice thick-
ness= 1.2mm, in-plane resolution 1mm. Cushions inside the head coil
were used to reduce head movement during scanning. All scans were
reviewed by a radiologist (H.A.R.) and 14 CU individuals were excluded
for abnormalities (e.g., hydrocephalus, prior craniotomy, CHS
rating> 4; Manolio et al., 1994).
FreeSurfer 6.0 (Fischl, 2012) was used for the purpose of defining an
“AD signature,” which consisted of a composite of thickness estimates
derived from the following regions of interest (ROIs) based on previous
research: entorhinal, inferior temporal, middle temporal, inferior par-
ietal, fusiform, and precuneus (Schwarz et al., 2016). Within Free-
Surfer, each gray matter voxel in an MRI image is mapped to a cortical
surface mesh and given a neuroanatomical label based on a probabil-
istic atlas from a manually labeled training set consisting of both
healthy younger and older adults as described in the software doc-
umentation (Fischl et al., 2002). We followed a quality control process
similar to that outlined by Schwarz et al. (2016) in which FreeSurfer
segmentation outputs were visually inspected by S.L.A. and R.P.C. for
severe errors, which included when FreeSurfer failed to complete
Table 1
Demographics and biomarkers.
Total sample ROC sample Concordance sample
CU A-T- AD A+ CU A-T- CU A+T- CU A+T+ MCI A+
N 325 20 20 229 24 16 16
Sex (male; %)^ 109 (33.5%) 10 (50.0%) 10 (50.0%) 71 (31.0%) 4 (16.7%) 4 (25.0%) 10 (62.5%)
Age (years) (mean (SD))* 61.9 (8.0) 66.7 (5.6) 66.6 (5.6) 59.7 (7.2) 63.1 (7.5) 68.5 (6.9) 73.0 (8.6)
Education (years) (mean (SD))+ 16.0 (2.5) 15.2 (2.8) 15.3 (2.8) 16.1 (2.4) 16.0 (2.8) 15.8 (2.4) 16.1 (2.8)
LN of CSF levels of Aβ42 (pg/mL) (mean (SD)) 6.4 (0.3) 6.7 (0.2) 5.8 (0.2) 6.6 (0.2) 6.0 (0.2) 6.0 (0.1) 5.9 (0.2)
CSF levels of ptau181 (pg/mL) (mean (SD)) 43.6 (17.9) 39.5 (8.6) 70.0 (21.2) 38.6 (10.0) 38.5 (13.3) 69.5 (16.5) 69.8 (37.0)
CSF levels of tau (pg/mL) (mean (SD)) 339.1 (204.1) 293.0 (62.9) 714.3 (262.4) 268.3 (84.3) 282.3 (112.5) 636.0 (178.1) 728.4 (347.7)
CSF levels of NfL (pg/mL) (mean (SD)) 731.9 (457.0) 692.9 (160.7) 1281.1 (717.9) 622.1 (286.5) 701.4 (373.8) 1025.7 (304.2) 1417.2 (1043.3)
AD Signature (z-score) (mean (SD)) 0.0 (1.0) 0.2 (0.7) −1.6 (1.0) 0.2 (0.9) −0.1 (0.7) −0.2 (0.8) −1.3 (1.0)
Hippocampal Volume (z-score) (mean (SD)) 0.0 (1.0) −0.2 (0.5) −1.4 (0.9) 0.3 (0.9) −0.2 (0.7) −0.1 (0.8) −1.4 (0.7)
Global Atrophy (z-score) (mean (SD)) 0.0 (1.0) 0.2 (0.8) 1.8 (0.8) −0.3 (0.7) 0.1 (0.9) 0.3 (1.0) 1.5 (1.0)
Notes: ROC= receiver operating characteristic; CU= cognitively unimpaired; AD=Alzheimer's disease; MCI=mild cognitive impairment; LN=natural-log;
CSF= cerebrospinal fluid; NfL= neurofilament light chain protein; ^there were significantly more females in the CU group than the MCI group; *the CU group was
significantly younger than the AD and MCI groups, but the MCI group was significantly older than the AD group; +one CU A-T- participant in the concordance
sample was missing education.
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topology correction (two participants with dementia due to AD) or a
significant portion of the cortical ribbon was placed incorrectly (two
MCI and two CU individuals). No manual correction of FreeSurfer was
performed and these six participants were excluded from analyses.
Volumetric estimates were derived from the T1-weighted IRSPGR
sequence. Tissue segmentation into CSF, gray matter, white matter, and
intracranial volume (ICV) was performed using SPM12 (www.fil.ion.
ucl.ac.uk/spm), which is an automated and completely reproducible
process (Ashburner et al., 2016). Brain (the sum of total gray matter
and white matter) and CSF segmentation was the objective of this
process and no failures (defined as gross tissue misclassification based
on visual inspection of the images by S.L.A) occurred. Hippocampal
volume was estimated using the completely automated FSL-FIRST al-
gorithm (Patenaude et al., 2011). Visual inspection of the hippocampal
segmentations by S.L.A. revealed that the output misclassified the
hippocampus in one dementia due to AD case that had significant
structural atrophy, and this participant was excluded from analyses. For
quantitative analyses, hippocampal volume was corrected for head size
by proportional scaling to total intracranial volume (brain plus CSF
volume derived from the SPM12 segmentation output). A simple mea-
sure of global atrophy was estimated as the ratio of CSF volume to brain
volume (total gray matter volume+ total white matter volume). In
order to compare the three metrics, they were scaled to have a mean of
0 and a standard deviation of 1.
2.3. Cerebrospinal fluid collection
Twenty-two mL of CSF were removed from the L3-L4 or L4-L5
vertebral interspace. These samples (sent in batches at two time points)
were analyzed at the Clinical Neurochemistry Laboratory at the
Sahlgrenska Academy of the University of Gothenburg, Sweden using
commercially available enzyme-linked immunosorbent assay methods.
CSF samples were assayed for Aβ42, ptau181, total tau, and NfL, and
corrected for batch when appropriate as described in Clark et al., 2018.
2.4. Amyloid and tau status determination
For the current study, the natural log of CSF Aβ42 < 6.156 was
defined as A+, whereas CSF levels of total tau> 461.26 or
ptau181 > 59.50 were defined as T+. We defined T+ based on either
CSF levels of total tau or ptau181 given the high correlation between
these two CSF measures in the current study (Spearman rank correla-
tion=0.916, p < .001). These cut-off values are based on prior ROC
analyses for discriminating CU individuals from those with a clinical
diagnosis of MCI or dementia due to AD (Clark et al., 2018).
2.5. Statistical analyses
Analyses were conducted in SPSS 23. First, ROC analyses were
performed to determine the sensitivity and specificity of hippocampal
volume, the AD signature, global atrophy, and CSF NfL for separating
A+ individuals with a clinical diagnosis of AD from A-T- CU in-
dividuals. The area under the curve (AUC), which may be defined as the
accuracy of the diagnostic test (values range from 0 to 1), was com-
puted for each metric. For each of these metrics, the value that max-
imized Youden's Index (sensitivity + specificity - 1) was chosen as the
threshold for N positivity. In the event that different cut-off values
evidenced identical Youden's Indices, the cut-off value with the highest
sensitivity was selected. Cohen's Kappa was then used to examine the
relationship between N positivity defined by NfL and each of the three
MRI-based measures of N. Cohen's Kappa was also used to examine the
relationships among the three MRI-based measures of N. We reported
positive percent agreement, negative percent agreement, and overall
percent agreement for each MRI-based measure in relation to NfL and in
relation to each other. Separate correlation matrices of all relevant
continuous measures of A, T, and N were also computed for the whole
sample (n=325) and for the concordance sample (n=285) using age-
adjusted partial correlations and Spearman rank correlations.
Finally, we wanted to examine the measures of N in the context of
staging across the AD continuum. Therefore, we performed Kruskal-
Wallis tests (Breslow, 1970) to determine if there was a significant re-
lationship between group membership (i.e., A-T- CU, A+T- CU,
A+T+ CU, A+ MCI, and A+ AD individuals) and each measure of N
(i.e., CSF NfL, AD signature, hippocampal volume, and global atrophy).
Post-hoc analyses comparing the A-T- CU group to each of the four
remaining groups were accomplished using Mann-Whitney U tests
(Mann and Whitney, 1947). Cliff's delta was used to compute the effect
size of each of the three MRI-based measures of N and NfL (Cliff, 1993).
Post-hoc analyses adjusting for age were also performed in the
context of staging across the entire AD continuum for Kruskal-Wallis
tests, Cliff's deltas, and Mann-Whitney U tests. First, using only the A-T-
CU group, separate regressions were performed with each measure of N
as an outcome in separate analyses and age as the predictor. The in-
tercept β, age β, and the square root of the mean square error (RMSE)
were saved. These parameters were then used for the whole sample
(n= 325) to get the predicted N value based on the A-T- CU group age-
related change. An individual's unadjusted z-score on each N metric was
converted to an age-adjusted z-score as follows:




Participants were on average 62 years old, 34% male, and highly
educated (see Table 1).
3.2. Determining cut-off values for each neurodegeneration measure1
CSF NfL (Fig. 1A), the AD signature (Fig. 1B), hippocampal volume
(Fig. 1C), and global atrophy (Fig. 1D) all significantly discriminated
between the A-T- CU (n=20) and A+ AD dementia (n= 20) groups
(see Table 2 for each metric's AUC, sensitivity, specificity, p-value, and
Youden's Index). Using the selected thresholds, NfL had the highest
sensitivity and AUC, whereas the AD signature had the highest speci-
ficity. However, examination of the AUC confidence intervals indicated
that all confidence intervals overlapped. That is, no one metric was
significantly better than any of the other metrics at discriminating be-
tween the groups. Please refer to Fig. 2 for boxplots of the neurode-
generation measures comparing A+ AD and A-T- CU individuals.
3.3. Relationship between NfL and the MRI-based measures of N
Using the cut-off values derived from the ROCs to define N positivity
(both for NfL and the MRI-based metrics), there was a significant re-
lationship between NfL and all three MRI-based metrics of N (i.e.,
hippocampal volume, the AD signature, and global atrophy), with
global atrophy having the highest concordance with NfL. Of note, the
agreement among the measures of N was relatively weak. See Tables
3A-3C for information regarding Cohen's Kappa, positive percent
agreement, negative percent agreement, and overall percent agreement
for the measures of N.
3.4. Correlations
Using the full sample, the AD signature, hippocampal volume, and
global atrophy were all significantly associated with CSF levels of Aβ42,
1 Results were unchanged when only A+T+ AD individuals and their
matched A-T- CU counterparts (n=36) were included in the analyses.
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Fig. 1. A-D represent ROC curves relating sensitivity and specificity of each measure for differentiating A-T- CU from A+ AD individuals; A) CSF NfL; B) the AD
signature; C) hippocampal volume; D) global atrophy.
Table 2
Diagnostic accuracy.
AUC (SE) AUC 95% CI P-Value Sensitivity Specificity Youden's J
NfL 0.943 (0.034) 0.877–1.000 < 0.001 95.0% 80.0% 0.750
AD signature 0.928 (0.041) 0.847–1.000 < 0.001 85.0% 90.0% 0.750
Hippocampal volume 0.885 (0.054) 0.780–0.990 < 0.001 80.0% 85.0% 0.650
Global atrophy 0.908 (0.048) 0.814–1.000 < 0.001 90.0% 80.0% 0.700
Notes: AUC= area under the curve; SE= standard error; NfL=neurofilament light chain protein;
AD=Alzheimer's disease.
S.L. Allison, et al. NeuroImage: Clinical 23 (2019) 101895
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Fig. 2. A-D represent box plots for each metric comparing A-T- CU to A+ AD individuals; A) CSF NfL; B) the AD signature; C) hippocampal volume; D) global
atrophy.
Table 3A





Positive % agreement Negative % agreement Overall % agreement Kappa
(p-value)
AD signature N+ 22 32 32.35% 85.25% 72.63% 0.189 (p=.001)
N- 46 185
Hippocampal volume N+ 24 33 35.29% 84.79% 72.98% 0.213 (p < .001)
N- 44 184
Global atrophy N+ 30 14 44.12% 93.55% 81.75% 0.429 (p < .001)
N- 38 203
Notes: NfL= neurofilament light chain protein; AD=Alzheimer's disease.
Table 3B
Concordance between AD signature and both hippocampal volume and global atrophy.
AD signature N+ AD signature N- Positive % agreement Negative % agreement Overall % agreement Kappa
(p-value)
Hippocampal volume N+ 22 35 40.74% 84.85% 76.49% 0.251 (p < .001)
N- 32 196
Global atrophy N+ 21 23 38.89% 90.04% 80.35% 0.311 (p < .001)
N- 33 208
Note: AD=Alzheimer's disease.
S.L. Allison, et al. NeuroImage: Clinical 23 (2019) 101895
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total tau, ptau181, and NfL (ps < 0.05). These associations were si-
milar, but attenuated, in the concordance sample. Of note, there was a
strong association between CSF total tau and ptau181 in both samples.
See Tables 4A-4D for the intercorrelations among the N metrics and CSF
biomarkers.
3.5. Staging across the AD continuum
Kruskal-Wallis tests demonstrated that there was a statistically sig-
nificant association between the four measures of N (i.e., CSF NfL, AD
signature, hippocampal volume, global atrophy) and AD continuum
group (ps < 0.001). Findings from Mann-Whitney U tests suggest that
the four measures of N performed similarly in terms of differentiating
A-T- CU individuals from both A+ MCI and A+ AD individuals
(ps < 0.001), with relatively large effect sizes noted (Cliff's deltas
≥0.741).
When comparing A-T- CU to A+T- CU individuals, only hippo-
campal volume was significantly different between these two groups
(p= .016, Cliff's delta= 0.298), although there was a non-significant
trend for both the AD signature (p= .051, Cliff's delta= 0.242) and
global atrophy (p= .088, Cliff's delta= 0.211). Finally, when com-
paring A-T- CU to A+T+ CU individuals, CSF NfL (p < .001, Cliff's
delta= 0.731) and global atrophy (p= .006, Cliff's delta= 0.410)
were significantly different between the two groups, with a non-
Table 3C
Concordance between global atrophy and hippocampal volume.
Global atrophy N+ Global atrophy N- Positive % agreement Negative % agreement Overall % agreement Kappa
(p-value)
Hippocampal volume N+ 23 34 52.27% 85.89% 80.70% 0.341 (p < .001)
N- 21 207
Table 4A
Age-adjusted partial correlations in the full sample (n= 325).
AD signature HC volume Global atrophy LN AB42 Total Tau Ptau181
AD signature
HC volume 0.252⁎⁎
Global atrophy −0.431⁎⁎ −0.433⁎⁎
LN AB42 0.358⁎⁎ 0.317⁎⁎ −0.329⁎⁎
Total Tau −0.347⁎⁎ −0.215⁎⁎ 0.251⁎⁎ −0.356⁎⁎
Ptau181 −0.231⁎⁎ −0.130+ 0.110+ −0.229⁎⁎ 0.878⁎⁎
NfL −0.185⁎ −0.148⁎ 0.263⁎⁎ −0.134+ 0.455⁎⁎ 0.336⁎⁎
Notes: AD=Alzheimer's disease; HC=hippocampal; LN=natural log; NfL= neurofilament light chain protein.
⁎⁎ p < .001.
⁎ p < .01.
+ p < .05.
Table 4B
Age-adjusted partial correlations in the concordance sample (n=285).
AD signature HC volume Global atrophy LN AB42 Total Tau Ptau181
AD signature
HC volume 0.110
Global atrophy −0.272⁎⁎ −0.325⁎⁎
LN AB42 0.247⁎⁎ 0.219⁎⁎ −0.162⁎
Total Tau −0.208⁎⁎ −0.089 0.033 −0.238⁎⁎
Ptau181 −0.120+ −0.031 −0.066 −0.106 0.878⁎⁎
NfL −0.116+ −0.068 0.173⁎ −0.045 0.407⁎⁎ 0.291⁎⁎
Notes: AD=Alzheimer's disease; HC=hippocampal; LN=natural log; NfL= neurofilament light chain protein.
⁎⁎ p < .001.
⁎ p < .01.
+ p < .05.
Table 4C
Spearman rank correlations in the full sample (n= 325).
AD signature HC volume Global atrophy LN AB42 Total Tau Ptau181
AD signature
HC volume 0.255⁎⁎
Global atrophy −0.380⁎⁎ −0.504⁎⁎
LN AB42 0.323⁎⁎ 0.330⁎⁎ −0.301⁎⁎
Total Tau −0.253⁎⁎ −0.258⁎⁎ 0.338⁎⁎ −0.106
Ptau181 −0.189⁎ −0.216⁎⁎ 0.270⁎⁎ −0.079 0.916⁎⁎
NfL −0.303⁎⁎ −0.348⁎⁎ 0.568⁎⁎ −0.156⁎ 0.653⁎⁎ 0.573⁎⁎
Notes: AD=Alzheimer's disease; HC=hippocampal; LN=natural log; NfL= neurofilament light chain protein.
⁎⁎ p < .001.
⁎ p < .01.
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significant trend for the AD signature (p= .058, Cliff's delta= 0.284).
It is important to note that examination of the confidence intervals for
Cliff's delta suggest that no one metric was significantly better than any
of the other metrics at discriminating between the groups, with the
exception that CSF NfL had a significantly larger effect size than the
hippocampus when discriminating between A-T- CU and A+T+ CU
individuals. See Table 5 for information regarding Mann-Whitney U p-
values, as well as Cliff's deltas and associated confidence intervals. See
Fig. 3 for boxplots of the N measures for each of the five groups (i.e., A-
T- CU, A+T- CU, A+T+ CU, A+ MCI, A+ AD).
3.6. Post-hoc analyses: staging across the AD continuum, adjusting for age
Results adjusting for age were largely unchanged, with the excep-
tion that there was no longer a trend for global atrophy when com-
paring A-T- CU to A+T- CU individuals (p= .562, Cliff's
delta= 0.072). Furthermore, only CSF NfL significantly differed be-
tween the A-T- CU and the A+T+ CU groups (p < .001, Cliff's
delta= 0.527). See Supplemental Table 1 for information regarding
Mann-Whitney U p-values, as well as Cliff's deltas and associated con-
fidence intervals. See Supplemental Fig. 2 for boxplots of the N mea-
sures for each of the five groups (i.e., A-T- CU, A+T- CU, A+T+ CU,
A+ MCI, A+ AD), adjusting for age.
4. Discussion
The current study sought to compare three commonly used MRI
morphometric operationalizations of N: global atrophy, hippocampal
volume, and an implementation of the AD signature from FreeSurfer.
These three metrics were selected for study because they are commonly
used in the field and prior literature has suggested all three are asso-
ciated with structural changes in AD (Dickerson et al., 2011; Dickerson
and Wolk, 2012; Fagan et al., 2009; Fox et al., 1999; Jack et al., 1992;
Schott et al., 2010; Schwarz et al., 2016; Storandt et al., 2009).
Regarding diagnostic accuracy, hippocampal volume, global atrophy,
and the thickness-based AD signature, along with CSF levels of NfL,
performed similarly in terms of differentiating A+ AD from A-T- CU
individuals. The highest sensitivity and AUC were reported for CSF NfL,
whereas the highest specificity was noted for the AD signature; how-
ever, the overlapping confidence intervals suggest no strong inferences
are warranted. The similar performance of these three metrics may be
due to the fact that at the dementia stage of AD, atrophy is present
throughout the brain (Scahill et al., 2002; Sluimer et al., 2009). In
summary, these findings suggest that for the purpose of identifying
individuals with dementia due to AD, N could be defined using any of
the three available MRI metrics or CSF NfL.
When applying the N cut-off values derived from the ROC analyses
to a larger sample containing A-T- CU, A+T- CU, A+T+ CU, and A+
MCI individuals, global atrophy had a relatively higher concordance
with CSF NfL than the other two MRI-based metrics of N; however, it is
important to emphasize that all three metrics had weak agreement with
CSF NfL and with each other (i.e., Cohen's Kappa values ≤0.429; Fleiss,
1971; Fleiss et al., 2013). Similarly, small to moderate inter-correla-
tions were observed for these four metrics of N. These findings are
consistent with prior research (Alexopoulos et al., 2014; Jack et al.,
2015; Toledo et al., 2014; Vos et al., 2016), suggesting that these
measures appear to provide different information related to N. Despite
this low level of agreement, results from Mann-Whitney U tests and
Cliff's deltas, unadjusted for age, indicated similar performance in terms
of differentiating the A-T- CU group from the AD continuum groups
(i.e., A+T- CU, A+T+ CU, A+ MCI, and A+ AD). These findings fit
with previous research indicating that different definitions of N produce
similar results, including that individuals defined as N+ using a
number of different approaches (e.g., hippocampal volume, thickness-
based AD signature, FDG-PET) performed more poorly on tests of
learning and memory than N- individuals (Jack et al., 2015).
The findings were largely unchanged when adjusting for age, with
the exception that there was no longer a trend for global atrophy when
Table 4D
Spearman rank correlations in the concordance sample (n=285).
AD signature HC volume Global atrophy LN AB42 Total Tau Ptau181
AD signature
HC volume 0.159⁎
Global atrophy −0.296⁎⁎ −0.444⁎⁎
LN AB42 0.240⁎⁎ 0.257⁎⁎ −0.211⁎⁎
Total Tau −0.150+ −0.167⁎ 0.236⁎⁎ 0.030
Ptau181 −0.090 −0.118+ 0.173⁎ 0.060 0.920⁎⁎
NfL −0.218⁎⁎ −0.279⁎⁎ 0.508⁎⁎ −0.044 0.618⁎⁎ 0.532⁎⁎
Notes: AD=Alzheimer's disease; HC=hippocampal; LN=natural log; NfL= neurofilament light chain protein.
⁎⁎ p < .001.
⁎ p < .01.
+ p < .05.
Table 5
Comparing measures of neurodegeneration across the AD continuum.
Statistic CU A-T- vs. CU A+T- CU A-T- vs. CU A+T+ CU A-T- vs. MCI A+ CU A-T- vs. AD A+
NfL Mann-Whitney U p-value 0.364 <0.001 <0.001 <0.001
Cliff's Delta 0.112 0.731 0.841 0.866
Confidence interval for Cliff's Delta −0.152–0.362 0.514–0.860 0.639–0.935 0.712–0.940
AD signature Mann-Whitney U p-value 0.051 0.058 < 0.001 <0.001
Cliff's Delta 0.242 0.284 0.741 0.859
Confidence interval for Cliff's Delta 0.008–0.451 0.012–0.516 0.469–0.885 0.727–0.930
Hippocampal volume Mann-Whitney U p-value 0.016 0.156 < 0.001 <0.001
Cliff's delta 0.298 0.212 0.866 0.810
Confidence interval for Cliff's Delta 0.084–0.485 −0.078–0.469 0.778–0.921 0.649–0.902
Global atrophy Mann-Whitney U p-value 0.088 0.006 < 0.001 <0.001
Cliff's Delta 0.211 0.410 0.856 0.915
Confidence interval for Cliff's Delta −0.056–0.450 0.051–0.675 0.507–0.964 0.644–0.982
Notes: NfL= neurofilament light chain protein; CU= cognitively unimpaired; MCI=mild cognitive impairment; AD=Alzheimer's disease.
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comparing A-T- CU to A+T- CU individuals. Furthermore, only CSF NfL
significantly differed between the A-T- CU and the A+T+ CU groups.
The best approach to account for “normal” (i.e., non-pathologic) age-
related change is yet to be determined in the literature for not only
structural MRI and CSF NfL, but also for other areas of study such as
cognition. Furthermore, previous investigations differ in whether and
how they adjust for age when examining N (e.g., Alexopoulos et al.,
2014; Jack et al., 2015; Toledo et al., 2014; Vos et al., 2016). In the
current study, we tried to estimate age-related changes by examining
the relationship between N and age in the A-T- CU group. We then
applied the parameters from this group to calculate age-adjusted values
of N for individuals across the AD continuum. The findings from the
current study do indicate that CSF NfL has the added benefit of similarly
distinguishing A-T- CU from A+T+ CU individuals, with and without
adjusting for age. Unfortunately, adjusting for age resulted in none of
the MRI-based measures differing between the A-T- CU and A+T+ CU
groups. Furthermore, this approach did not account for other patho-
logic changes (e.g., cerebrovascular disease) that may impact estimates
of N in the context of aging. The field would benefit from future studies
with larger groups across the AD continuum to determine the best ap-
proach for adjusting for non-pathologic aging and whether any of the
three MRI-based metrics of N is preferable for defining N when ac-
counting for age-associated changes.
Although the present results indicate that any of the three MRI-
based measures may be used to define N across the AD continuum, the
measure of global atrophy in the current study may be preferable to the
other measures for methodological reasons. First, the global atrophy
metric is less affected by the limitations of current segmentation tech-
niques. In particular, previous research indicates reduced gray to white
contrast with aging, which will affect the estimates of any metric re-
quiring segmentation of gray from white matter structures, and may
result in less accurate volumetric and thickness estimates (Fischl et al.,
2002). Because the measure of global atrophy was a ratio of CSF vo-
lume to white and gray matter volumes (summed), this metric is by
design impervious to gray and white matter segmentation uncertainties
that were inherent to thickness and hippocampal volumetric estimates.
This benefit of the global atrophy estimate is worth emphasizing given
existing literature demonstrating that white matter signal intensity
declines with age (Salat et al., 2009) and is impacted by disease status,
with AD patients evidencing lower signal intensity and gray to white
matter contrast than their CU counterparts (Westlye et al., 2009). To-
gether, these findings would suggest that estimates that do not rely on
differentiating gray from white matter may be preferable when defining
N across the AD continuum.
In contrast to the hippocampal volumetric estimate, both the global
atrophy metric and the AD signature had the added benefit of not
needing to correct for head size as it was a ratio of CSF to white and
gray matter volumes (summed). In the current study, we controlled for
head size by dividing hippocampal volume by intracranial volume. A
number of other approaches have been used to correct for head size
variation (e.g., Buckner et al., 2004; O'Brien et al., 2011; Raz et al.,
1997), and currently, there is no universally agreed upon method.
Fig. 3. A-D represent box plots for each metric comparing the different groups (CU A-T-, CU A+T-, CU A+T+, MCI A+, AD A+); A) CSF NfL; B) the AD signature;
C) hippocampal volume; D) global atrophy.
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Considering that the method employed to account for head size can
result in significant variability across studies, a metric like global
atrophy, which does not require head size correction, may be preferable
when defining N across the AD continuum.
Even though the thickness-based AD signature did not require head
size correction, the potential uncertainties related to the accuracy and
reliability of FreeSurfer may make this measure less than optimal for
defining N across the AD continuum. Specifically, prior research sug-
gests some problems with the accuracy of atlas-based FreeSurfer gen-
erated estimates in the temporal lobe (a region included in the current
AD signature; Desikan et al., 2006; Oguz et al., 2008). Furthermore,
although the AD signature was composed of estimates from a number of
regions, a prior investigation indicates lower reliability for regions with
smaller surface areas, such as the entorhinal cortex, which was included
in the AD signature in this study (Desikan et al., 2006). For these rea-
sons, global atrophy may be preferable to the thickness-based AD sig-
nature derived from FreeSurfer for defining N across the AD continuum.
Despite the emphasis of the present study on MRI-derived measures
of N and CSF NfL, it is important to highlight the strong association
noted between total tau and ptau181 in the current analysis. The AT(N)
framework developed by Jack et al. (2018) classifies CSF total tau as a
measure of N, whereas ptau181 is considered a metric of T. Despite prior
investigations indicating that CSF levels of total tau and ptau181 may
diverge in other neurodegenerative conditions, such as Creutzfeldt-
Jakob disease (Skillbäck et al., 2014) and certain clinical variants of
frontotemporal dementia (Meeter et al., 2018), treating CSF measures
of total tau and ptau181 as reflecting N and T, respectively, may be less
helpful in terms of staging individuals across the AD continuum given
their strong association. Within the context of the current findings, a
different measure of N, such as one obtained using structural MRI or
CSF NfL, may be preferable to the use of total tau for defining N in
individuals across the AD continuum.
The current findings should be considered within the context of
several limitations. First, even though the present work suggests similar
effect sizes for the four measures when defining N across the AD con-
tinuum, this study only examined CSF NfL and three out of a potentially
very large number of candidate MRI metrics of atrophy that have been
presented in the literature (Atiya et al., 2003; Frisoni et al., 2010). In
addition to constraining our examination of N to four measures, each of
the four measures was examined independently. There is some research
to suggest that a combination of N markers may be the best approach
when defining N. For example, relatively recent work suggests that A+
CU individuals who are N+ based on both CSF total tau and hippo-
campal volume tend to be at greater risk of clinical decline when
compared to A+ CU individuals who are N+ on only CSF total tau or
hippocampal volume (Vos et al., 2016). Additionally, a recent study
found that a combined MRI measure of atrophy and cerebrovascular
disease was associated with PET amyloid imaging, CSF biomarkers, and
neuropathology at autopsy in individuals across the AD continuum
(Brickman et al., 2018). Subsequent work should explore how in-
dependent measures compare to a combination of measures (e.g.,
structural MRI estimates, CSF levels of NfL, FDG-PET, and/or diffusion
tensor imaging) for defining N across the AD continuum. Considering
that individuals with AD frequently have cerebrovascular disease
(Kapasi et al., 2017), future AD-related research could compare dif-
ferent N measures in conjunction with measures of cerebrovascular
disease (e.g., cerebral blood flow and pulsatility) (Gu et al., 2005).
Limitations related to the sample in this study should also be ac-
knowledged. Although a strength of the current study is that individuals
in the A+ AD group were matched to A-T- CU individuals on age, sex,
and education, the sample sizes for the groups were relatively small
(i.e., n=20 in each of the AD and biomarker-negative CU groups).
Similar small sample sizes were observed for the other groups across the
AD continuum (i.e., n= 20 A+T- CU, n=16 A+T+ CU, and 16 A+
MCI). Furthermore, the participants were generally well educated with
a mean education level of approximately 16 years. These constraints
may limit the generalizability of the current findings. Additional re-
search with a larger and more diverse sample is needed. In particular,
considering that we constrained our examination to individuals who
were along the AD continuum, as well as excluded CU individuals with
significant cerebrovascular disease, subsequent research is needed to
determine the optimal way to define N in individuals with other neu-
rodegenerative conditions, including those who are A-T+. Finally, fu-
ture research using the three MRI-based metrics from the current study
may also examine the degree to which biomarker-positive CU in-
dividuals who are N+ go on to develop dementia due to AD.
A final limitation of the current study is that the cut-off values used
to define N were determined based on their ability to differentiate A+
individuals with a clinical diagnosis of probable AD from A-T- CU in-
dividuals. These cut-off values were then used in a subsequent analysis
to examine the concordance between the three MRI-based metrics and
CSF NfL. In an ideal scenario, there would be some “true” cut-off value
of NfL, or another marker of N, that defines the presence of neurode-
generation independent from clinical status. We would then use this
cut-off value to evaluate our MRI-based metrics. Unfortunately, no
agreed upon measure currently exists for NfL or any other measure of
neurodegeneration (separate from clinical status) for defining N (Jack
et al., 2016, 2018). Future work should reexamine this question once an
independent reference standard becomes available.
Within the context of these limitations, the current study suggests
that the global atrophy metric may represent a convenient MRI-based
measure for defining N across the AD continuum. Specifically, global
atrophy was similar to hippocampal volume and the AD signature for
differentiating A+ AD dementia individuals from A-T- CU individuals,
as well as for differentiating A-T- CU individuals from A+T- CU,
A+T+ CU, and A+ MCI. The fact that the global atrophy metric re-
quired less human and computational resources and is not affected by
methodological issues that may affect complex approaches (e.g., gray
from white matter demarcation and atlas based parcellation) also favors
the use of global atrophy as a measure of neurodegeneration. The
choice of an MRI neurodegeneration metric employed in any particular
study will depend on the specific research question and should consider
the precision, reliability, and complexity of the approach given the
quality of the input image data. Taken together, these findings provide
justification for considering global atrophy as a general and robust MRI-
based metric for evaluating N across the AD continuum.
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.nicl.2019.101895.
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